Remedy Robotics AI-powered endovascular robotic system N1

Remedy Robotics Raises $62M to Bring AI-Powered Endovascular Surgery to Every Hospital

November 18, 2026

A Robot That Could Change Who Survives a Stroke

Cardiovascular disease is the leading cause of death worldwide, claiming nearly 20 million lives every year. Stroke is one of its most devastating expressions. The window for intervention is narrow, the expertise required is rare, and the hospitals capable of performing endovascular procedures are few. By one estimate, only 2.8 percent of eligible stroke patients worldwide currently receive endovascular treatment.

That gap is what San Francisco-based Remedy Robotics was built to close. On November 16, 2026, the company announced a $62 million Series B to accelerate the work.

What Remedy Robotics Has Built

Remedy Robotics built the N1 System: an AI-enabled robotic platform designed to perform entire endovascular procedures robotically. The N1 integrates precision catheter-driving hardware with a machine-learning software stack that analyzes preoperative imaging before a case begins, simulates patient-specific vascular anatomy, and during a live procedure executes real-time 3D-to-2D image registration with sub-millimeter precision.

The result is a system built for on-site, remote, and progressively autonomous operation across neurovascular, coronary, and peripheral vascular indications. A specialist at a remote hub can guide the robot through delicate cerebral arteries in a hospital hundreds of miles away. In October 2025, Remedy announced the first remote neurointerventional procedures completed using the N1 System. The company now works with more than 100 hospitals worldwide and holds 48 issued patents covering its platform. The N1 remains under development and is not currently available for clinical use in any jurisdiction.

Who Is Backing the Round

DCVC led the Series B. New institutional investors include UC Investments, the University of California investment office, alongside Skip Capital and Australian pension fund Hostplus. Existing backers Build Collective, Blackbird, Divergent Capital, and KdT Ventures also increased their commitment.

The composition of the investor group is notable. UC Investments represents the same university system that will host Remedy Robotics planned pivotal clinical trial for neurovascular intervention. That partnership, alongside strategic alliances with SVIN Mission Thrombectomy and the Australian Stroke Alliance, signals that Remedy is not building toward regulatory milestones in isolation.

What the Capital Is For

Remedy has identified three primary uses for the Series B proceeds. First, funding a planned pivotal clinical trial with the University of California network, a critical step on the path toward FDA approval. Second, expanding prototype N1 System deployments across its clinical-partner network. Third, continuing development of the platform AI and autonomous capabilities.

Stroke alone carries an annual economic burden of approximately $891 billion worldwide through healthcare costs and lost productivity. The human argument and the economic argument point in the same direction: endovascular care needs to reach far more patients than it currently does, and doing that at scale requires decoupling specialist expertise from physical bedside presence.

Why It Matters Beyond the Round

Remedy sits at the intersection of several converging trends: the maturation of physical AI, the commercialization of medical robotics, and a growing recognition among institutional investors that healthcare access is a fundable problem. The company ability to draw capital from a university investment office whose institution will also run the clinical trial speaks to the depth of integration it has achieved with the academic medical community.

Cardiovascular emergencies are time-critical. Patient outcomes vary sharply based on proximity to specialized care, even in countries with well-developed specialist networks. Remedy technology is designed to change that equation for a patient in rural Arkansas or in Lagos, Nigeria, where endovascular intervention is almost entirely unavailable.

The road ahead involves a pivotal trial, FDA review, and sustained execution. But with $62 million, partnerships inside the University of California system, and a platform that has already performed the first remote neurointerventional procedures, Remedy Robotics is now better positioned than ever to push that goal forward.

Source: PR Newswire, November 16, 2026 — https://www.prnewswire.com/news-releases/remedy-robotics-raises-62-million-series-b-to-bring-life-saving-cardiovascular-intervention-to-patients-everywhere-302939871.html

Jason Lim

Jason Lim

I wanted more than just survival—I wanted control, options, and a life on my terms. The obsession with this goal led me to several places and acquired unique skillsets, in order to accomplish my goals. I found the secrets in my rock bottom, now I want to share them with you

Instagram logo icon
Youtube logo icon
Back to Blog